AVRO logo

AVROBIO (AVRO) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

21 June 2018

Indexes:

Not included

Description:

AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Aug 09, 2024

Recent annual earnings:

Mar 23, 2023
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

June 21, 2024

Analyst ratings

Recent major analysts updates

18 Dec '23 Mizuho
Neutral
13 July '23 Wells Fargo
Overweight
12 July '23 Wedbush
Neutral
24 Mar '23 Needham
Buy
24 Mar '23 Mizuho
Buy
08 Dec '22 BTIG
Buy
17 May '22 Needham
Buy
11 May '22 Barclays
Overweight
06 Jan '22 Mizuho
Buy
05 Jan '22 Needham
Buy

Screeners with AVRO included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Similar stocks

Is AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year?
Is AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year?
Is AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year?
AVRO
Zacks Investment Research08 November 2023

Here is how AVROBIO, Inc. (AVRO) and Crinetics Pharmaceuticals, Inc. (CRNX) have performed compared to their sector so far this year.

Is AVROBIO (AVRO) Outperforming Other Medical Stocks This Year?
Is AVROBIO (AVRO) Outperforming Other Medical Stocks This Year?
Is AVROBIO (AVRO) Outperforming Other Medical Stocks This Year?
AVRO
Zacks Investment Research23 October 2023

Here is how AVROBIO, Inc. (AVRO) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.

Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year?
Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year?
Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year?
AVRO
Zacks Investment Research06 October 2023

Here is how AVROBIO, Inc. (AVRO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.

Avrobio: Net-Net Biotech Pursuing Strategic Alternatives
Avrobio: Net-Net Biotech Pursuing Strategic Alternatives
Avrobio: Net-Net Biotech Pursuing Strategic Alternatives
AVRO
Seeking Alpha12 August 2023

After monetizing one of its pipeline candidates, Avrobio has cash well in excess of its market cap. The company announced its search for strategic alternatives recently. The process could close its valuation gap soon. There is potential for significantly more value if Avrobio can also monetize its remaining candidates.

AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46%
AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46%
AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46%
AVRO
Zacks Investment Research13 July 2023

AVROBIO (AVRO) announces its decision to halt all development programs in its quest to explore strategic alternatives. The stock of the company surges 46% in response on Wednesday.

How to Handle Penny Stocks Volatility in 2023
How to Handle Penny Stocks Volatility in 2023
How to Handle Penny Stocks Volatility in 2023
AVRO
PennyStocks23 May 2023

Penny stocks continue to offer incredible opportunities for investors in 2023. As high-growth, micro-cap equities, they have the potential to outperform traditional stocks, particularly given their inherent affordability, which allows for a broader, more diversified portfolio.

Why Is AVROBIO (AVRO) Stock Up 83% Today?
Why Is AVROBIO (AVRO) Stock Up 83% Today?
Why Is AVROBIO (AVRO) Stock Up 83% Today?
AVRO
InvestorPlace22 May 2023

AVROBIO (NASDAQ: AVRO ) stock is seeing massive gains on Monday as the company sells one of its gene therapies to Novartis (NYSE: NVS ). This deal has Novartis agreeing to pay $87.5 million in cash to AVROBIO for an investigational hematopoietic stem cell ( HSC ) gene therapy program.

FAQ

  • What is the primary business of AVROBIO?
  • What is the ticker symbol for AVROBIO?
  • Does AVROBIO pay dividends?
  • What sector is AVROBIO in?
  • What industry is AVROBIO in?
  • What country is AVROBIO based in?
  • When did AVROBIO go public?
  • Is AVROBIO in the S&P 500?
  • Is AVROBIO in the NASDAQ 100?
  • Is AVROBIO in the Dow Jones?
  • When was AVROBIO's last earnings report?
  • When does AVROBIO report earnings?
  • Should I buy AVROBIO stock now?

What is the primary business of AVROBIO?

AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

What is the ticker symbol for AVROBIO?

The ticker symbol for AVROBIO is NASDAQ:AVRO

Does AVROBIO pay dividends?

No, AVROBIO does not pay dividends

What sector is AVROBIO in?

AVROBIO is in the Healthcare sector

What industry is AVROBIO in?

AVROBIO is in the Biotechnology industry

What country is AVROBIO based in?

AVROBIO is headquartered in United States

When did AVROBIO go public?

AVROBIO's initial public offering (IPO) was on 21 June 2018

Is AVROBIO in the S&P 500?

No, AVROBIO is not included in the S&P 500 index

Is AVROBIO in the NASDAQ 100?

No, AVROBIO is not included in the NASDAQ 100 index

Is AVROBIO in the Dow Jones?

No, AVROBIO is not included in the Dow Jones index

When was AVROBIO's last earnings report?

AVROBIO's most recent earnings report was on 9 August 2024

When does AVROBIO report earnings?

The date for AVROBIO's next earnings report has not been announced yet

Should I buy AVROBIO stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions